Daiichi Sankyo and biotech firm Arqule are to move their lung cancer treatment ARQ 197 into phase III trials. The …
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns

